Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel W Cramer

Showing results (151-160 of 233) with videos related to

Pageof 24
Sort By:
International Journal of Epidemiology|April 10, 2013
Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studiesWeiva Sieh, Shannon Salvador, Valerie McGuire, et al.
Journal of the National Cancer Institute|February 8, 2014
Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association ConsortiumBritton Trabert, Roberta B Ness, Wei-Hsuan Lo-Ciganic, et al.
British Journal of Cancer|August 18, 2017
History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief reportAlbina N Minlikeeva, Jo L Freudenheim, Rikki A Cannioto, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 18, 2018
Anti-CA15.3 and Anti-CA125 Antibodies and Ovarian Cancer Risk: Results from the EPIC CohortDaniel W Cramer, Raina N Fichorova, Kathryn L Terry, et al.
International Journal of Cancer|February 24, 2018
Tumor-associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluationRudolf Kaaks, Renée Turzanski Fortner, Anika Hüsing, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 4, 2011
MicroRNA processing and binding site polymorphisms are not replicated in the Ovarian Cancer Association ConsortiumJennifer Permuth-Wey, Zhihua Chen, Ya-Yu Tsai, et al.
Journal of Ovarian Research|November 28, 2019
Development and validation of circulating CA125 prediction models in postmenopausal womenNaoko Sasamoto, Ana Babic, Bernard A Rosner, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 6, 2019
Predicting Circulating CA125 Levels among Healthy Premenopausal WomenNaoko Sasamoto, Ana Babic, Bernard A Rosner, et al.
American Journal of Epidemiology|May 22, 2024
Racial and ethnic differences in epithelial ovarian cancer risk: an analysis from the Ovarian Cancer Association ConsortiumNicola S Meagher, Kami K White, Lynne R Wilkens, et al.
Journal of Ovarian Research|March 22, 2017
Correlates of circulating ovarian cancer early detection markers and their contribution to discrimination of early detection models: results from the EPIC cohortRenée T Fortner, Allison F Vitonis, Helena Schock, et al.
Pageof 24

Showing results (151-160 of 233) with videos related to

Sort By:
Pageof 24
International Journal of Epidemiology|April 10, 2013
Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studiesWeiva Sieh, Shannon Salvador, Valerie McGuire, et al.
Journal of the National Cancer Institute|February 8, 2014
Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association ConsortiumBritton Trabert, Roberta B Ness, Wei-Hsuan Lo-Ciganic, et al.
British Journal of Cancer|August 18, 2017
History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief reportAlbina N Minlikeeva, Jo L Freudenheim, Rikki A Cannioto, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 18, 2018
Anti-CA15.3 and Anti-CA125 Antibodies and Ovarian Cancer Risk: Results from the EPIC CohortDaniel W Cramer, Raina N Fichorova, Kathryn L Terry, et al.
International Journal of Cancer|February 24, 2018
Tumor-associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluationRudolf Kaaks, Renée Turzanski Fortner, Anika Hüsing, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 4, 2011
MicroRNA processing and binding site polymorphisms are not replicated in the Ovarian Cancer Association ConsortiumJennifer Permuth-Wey, Zhihua Chen, Ya-Yu Tsai, et al.
Journal of Ovarian Research|November 28, 2019
Development and validation of circulating CA125 prediction models in postmenopausal womenNaoko Sasamoto, Ana Babic, Bernard A Rosner, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 6, 2019
Predicting Circulating CA125 Levels among Healthy Premenopausal WomenNaoko Sasamoto, Ana Babic, Bernard A Rosner, et al.
American Journal of Epidemiology|May 22, 2024
Racial and ethnic differences in epithelial ovarian cancer risk: an analysis from the Ovarian Cancer Association ConsortiumNicola S Meagher, Kami K White, Lynne R Wilkens, et al.
Journal of Ovarian Research|March 22, 2017
Correlates of circulating ovarian cancer early detection markers and their contribution to discrimination of early detection models: results from the EPIC cohortRenée T Fortner, Allison F Vitonis, Helena Schock, et al.
Pageof 24